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Melatonin activates two brain G-protein coupled receptors, MT1 andMT2, whose differential roles in the sleep–wake cycle remain to be
defined. The novel MT2 receptor partial agonist, N-{2-[(3-methoxyphenyl) phenylamino] ethyl} acetamide (UCM765), is here shown to
selectively promote non-rapid eyemovement sleep (NREMS) in rats andmice. The enhancement ofNREMSbyUCM765 is nullified by the
pharmacological blockade or genetic deletion ofMT2 receptors.MT2 , but notMT1 , knock-outmice showadecrease inNREMS compared
to the wild strain. Immunohistochemical labeling reveals thatMT2 receptors are localized in sleep-related brain regions, and notably the
reticular thalamic nucleus (Rt). Microinfusion of UCM765 in the Rt promotes NREMS, and its systemic administration induces an
increase in firing and rhythmic burst activity of Rt neurons, which is blocked by the MT2 antagonist 4-phenyl-2-propionamidotetralin.
Since developing hypnotics that increase NREMS without altering sleep architecture remains a medical challenge, MT2 receptors may
represent a novel target for the treatment of sleep disorders.
Introduction
Insomnia is a common public health problem, with a prevalence
ranging from 11 to 16% (Leland, 2006; Morin et al., 2006). In
mammals, normal sleep is characterized by an orderly pro-
gression from wakefulness to non-rapid eye movement sleep
(NREMS), also referred to as slow-wave sleep (SWS), and then to
paradoxical sleep or rapid eye movement sleep (REMS). SWS is
also known as “restorative sleep” since it is involved in memory
consolidation (Stickgold, 2005; Marshall et al., 2006) and meta-
bolic regulation (Tasali et al., 2008).
Currently used hypnotic drugs, such as benzodiazepines (BZ)
and derivates (i.e., zopiclone), act on the GABAergic system, af-
fecting both NREMS and REMS, thus altering sleep architecture
(Lancel, 1999). Most of them induce next-day cognitive impair-
ments and abuse liability. Antidepressants also alter REMS den-
sity, but with little or no effect on SWS (Mayers and Baldwin,
2005). Developing new effective hypnotic drugs selectively in-
creasing NREMS without altering the whole sleep architecture
therefore remains a scientific and medical challenge.
Melatonin (N-acetyl-5-methoxytryptamine; MLT), synthe-
sized by the pineal gland, has been reported to have hypnotic
effects in humans, although results are still controversial (Brzez-
inski et al., 2005; Buscemi et al., 2006). Animal studies have dem-
onstrated that MLT reduces time to sleep onset and increases
both NREMS and REMS (Holmes and Sugden, 1982; Mirmiran
and Pevet, 1986), with both effects being blocked by the GABAA
receptor antagonists flumazenil and picrotoxin (Wang et al.,
2003a). Other studies showed little or no effect (Mailliet et al.,
2001; Wang et al., 2003b).
The physiological actions of MLT in brain are mediated by
two high-affinity G-protein-coupled receptors, MT1 and MT2,
whose respective roles in sleep remain to be defined. Three novel
nonselective MT1/MT2 agonists, TIK-301 (Zemlan et al., 2005),
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ramelteon (Mini et al., 2007), and tasimelteon (Rajaratnam et al.,
2009), have been tested in humans for the treatment of insomnia;
all three significantly reduced the latency to sleep, but were less
potent in potentiating the long-term enhancement of total sleep
time and without selectivity toward NREMS or REMS. The non-
selective antidepressantMT1/MT2 agonist agomelatine improves
sleep after 6 weeks of treatment (Quera Salva et al., 2007), but its
mechanisms of action remain to be elucidated, as it also binds to
serotonergic 5-HT2B and 5-HT2C receptors, already known to be
involved in sleep (DenBoer et al., 2006). Considering their lack of
selectivity, none of the above compounds allow for a selective
pharmacological investigation of the role of brain MT1 and MT2
melatonin receptors.
In the present study, we examine the effects of the partial MT2
receptor agonistN-{2-[(3-methoxyphenyl) phenylamino] ethyl}
acetamide (UCM765) (Rivara et al., 2007) on the sleep–wake
cycle of rats and that of mice lacking MT1 or MT2 receptors,
disclosing a selective NREMS promoting effect of UCM765. In
addition, having found MT2 receptors to be abundant in the
reticular thalamic nucleus (Rt), we combined extracellular re-
cording in anesthetized rats, as well as bilateral intrathalamic
microinfusion and EEG/EMG recording in freely moving rats, to
demonstrate that UCM765 induces NREMS by modulating the
electrical activity of Rt.
Materials andMethods
All experimental procedures were conducted in accordance with the
guidelines of the Canadian Council on Animal Care, and the protocols
were approved by the Animal Care Committee at McGill University.
Monitoring of the sleep–wake cycle. These experiments were performed
in adult male Sprague Dawley rats (225–340 g; Charles River Laborato-
ries), adult male C3H/He wild-type (WT) mice (28–35 g; Charles River
Laboratories), and mice of the same genetic background lacking MT1
(Liu et al., 1997) or MT2 receptors (Jin et al., 2003), kindly provided by
Drs.Weaver and Reppert (University ofMassachusetts,Worcester,MA).
The knock-out (KO) mice were originally derived from a 129/sv KO
mouse bred to a C3H female; heterozygous males from each generation
were backcrossed exclusively to C3H females (10 generations and more
of backcrossing), and male and female heterozygous were interbred to
produceC3HWTandKOmice on theC3Hbackground (Jin et al., 2003).
All animals were housed in small groups at 22°C,with ad libitum access
to food andwater, andmaintained under a 12 h light/dark cycle (lights on
at 7:30 AM; lights off at 7:30 P.M.). They were housed in separate cages
after surgery.
Surgery. Rats andmice were deeply anesthetized with equithesin (1 ml
per 300 g, i.p.) and placed in a stereotaxic frame. For EEG monitoring,
three stainless-steel epidural electrodes were positioned through 1.5 mm
burr holes: one over the parietal cortex on each side, and the third (as a
reference) in the right parietal cortex. In rats, their respective locations
relative to bregmawere2mmanteroposterior (AP) and3mm lateral
(L),7mmAP and3mmL, and4.5 mmAP and3mmL, accord-
ing to Paxinos and Watson (2006). In mice, their respective locations
relative to bregmawere0.95mmAP and2mmL,2.85mmAP and
2 mm L, and 1.9 mm and 2 mm L, according to Franklin and
Paxinos (1997). To monitor EMG signals, three flexible stainless-steel
wire electrodes, isolated except for the last 3–4 mm, were implanted
into the neck muscles (two bilaterally and one in the middle). Wires
and connector were fixed to the skull with dental acrylic
(Coltene/Whaledent).
After 24 h of recovery and during the next 5 d, the rats or mice were
placed in a recording chamber and connected to a flexible cable for
several hours daily, to habituate before the recording of sleep parameters.
EEG and EMG data analysis. EEG/EMG signals were amplified at a
total gain of 10.000 and filtered locally (EEG, low filter, 1Hz; high, 1 kHz;
EMG, low filter, 30 Hz; high, 3 kHz; Grass, P55), digitized using a CED
power 1401 converter and Spike 2 software (CED) (Urbain et al., 2006),
stored with a resolution of 128 Hz, and displayed on a PC monitor.
Consecutive 2 s epochs were subjected to a fast Fourier transform (FFT),
and EEG power spectra density was computed in the frequency range of
0–64 Hz.
The three classical vigilance states as described in the rat were discrim-
inated on the basis of the cortical EEG and neck EMG (Jones, 2005).
Wakefulness was identified by a low-amplitude and desynchronized
EEG, with sustained EMG activity. NREMS was clearly distinguished by
high-voltage delta waves (1–4 Hz) and spindles associated with a weak
EMG activity. REMS was characterized by a low-amplitude EEG with a
pronounced theta rhythm (6–11 Hz) and a complete loss of nuchal
muscle tone. To avoid transitional periods such as drowsiness, only pe-
riods of typical stationary EEG and EMG lasting at least 10 s were con-
sidered for further analyses of wakefulness, NREMS, and REMS.
The latency to NREMS was defined as the time from the first injection
(6:00 P.M.) of vehicle, UCM765, N-{2-[(3-methoxyphenyl)methylamino]
ethyl} acetamide (UCM793), or diazepam (DZ) to the first NREMS episode
longer than 2min. The latency toREMSwas the time from the first injection
to the first episode of REMS lasting10 s. Power spectra of the correspond-
ing EEGswere then calculated by using the FFTof each 10 s epoch. Power in
the 0–25Hz range of artifact-free epoch was averaged, and themean values
were plotted in 0.5 Hz bins.
To determine the variations in power spectra induced by the pharma-
cological treatment or MLT receptor genetic deletion, the power densi-
ties were summed over the frequency band of 0–25Hz (total power). The
data were then standardized by expressing all power spectral densities at
the different 0.5Hz bin frequency ranges (delta, theta, sigma, and beta) as
a percentage relative to the total power of the same epoch [modified from
the study by Parmentier et al. (2002)]. Frequency ranges for sigma and
beta bands were 11–15 and 15–18 Hz, respectively. Spindle-wave epi-
sodes (group of rhythmicwaves characterized by a progressive increasing
then decreasing amplitude, with activity between 10 and 14 Hz) were
readily detected after bandpass filtering of the EEG at frequencies
between 10 and 15 Hz (Espinosa et al., 2008). Spindles were counted
manually in 1 s epochs within all NREMS episodes lasting 2 min,
using Spike2 software.
Pharmacological treatments. For experiments in which the EEG and
EMG were recorded from 6:00 to 9:00 P.M., vehicle (DMSO 70% and
30% saline, 0.2 ml for rats, 0.1 ml for mice), DZ (2 mg/kg), UCM765 (40
mg/kg), UCM793 (40, 60, or 80mg/kg), or theMT2 antagonist 4-phenyl-
2-propionamidotetralin (4P-PDOT; 10mg/kg) were injected subcutane-
ously at the beginning of the recording period. For 24 h experiments with
UCM765 at different doses, 20, 40, or 60 mg/kg was injected subcutane-
ously every 4 h, starting at 6:00 P.M. For comparison with DZ, 40 mg/kg
UCM765 was injected subcutaneously every 4 h starting at 6:00 P.M.,
whereas a sleep promoting dose of DZ [2 mg/kg (Gottesmann et al.,
1998)], was injected subcutaneously at 6:00 P.M. and 6:00 A.M., given
the long, 6–8 h half-life of DZ. Vehicle was then injected at 10:00 P.M.,
2:00 A.M., 10:00 A.M., and 2:00 P.M. tomimic the sequence of UCM765
injection.
Immunolabeling of MT2 receptors. Polyclonal anti-MT2 antibodies
were produced as described previously (Angeloni et al., 2000) and affinity
purified. In preliminary immunohistochemical experiments on brain
tissue from wild-type and MT2 KO mice, only ubiquitous, nonspecific
staining of neurons and glial cells was observed (results not shown),
precluding the use of these antibodies in this species. Sequence alignment
between human and ratMT2 proteins was suggestive of interspecies con-
servation of an immunogenic epitope (see Fig. 5, top left). In Western
blots of rat brain regions (Angeloni et al., 2000), the antibodies reacted
with a band of 40 kDa, corresponding to the predicted molecular
weight of the native MT2 receptor protein (see Fig. 5, top right).
Adult male Sprague Dawley rats (250  50 g; n  5) were deeply
anesthetized with sodium pentobarbital (80 mg/kg, i.p.) and perfused
through the heart with 200ml of fixative solution [4%paraformaldehyde
(PFA) and 0.25% acrolein in 0.1 mM phosphate buffer (PB), pH 7.4]
followed by 500ml of 4%PFA inPB. The brainwas removed, postfixed in
4% PFA (60 min, 4°C), and washed in PBS (0.9%NaCl in 50 mM PB, pH
7.4). Sections (50mthick)were cutwith a vibratome andprocessed free
floating for immunoperoxidase labeling as follows. Sections were im-
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mersed in 3% hydrogen peroxide (H2O2) for 30 min, rinsed in PBS,
immersed in 0.1% sodium borohydride in PBS for 30min, rinsed in PBS,
and preincubated for 2 h in a blocking solution (BS) of PBS containing
10%normal goat serum (Vector Laboratories), 0.5% gelatin, 0.01%BSA,
and 0.3% Triton X-100. Sections were then washed in PBS, incubated
overnight withMT2 antibody (1:250 in BS), rinsed in PBS, incubated for
2 h with biotinylated goat anti-rabbit IgGs 1:1000 in BS (Jackson Immu-
noResearch), and incubated for 1 h in a 1:1000 dilution of horseradish
peroxidase-conjugated streptavidin (Jackson ImmunoResearch). After
washes in 0.05 mM Tris-buffered saline (TBS), pH 7.4, MT2 labeling was
revealed 2–5 min in TBS containing 0.05% 3,3-diaminobenzidine tetra-
hydrochloride and 0.01% H2O2. The reaction was stopped in TBS. Sec-
tions were then air dried on gelatin-coated slides, dehydrated in ethanol,
cleared in toluene, and mounted with DPX (Fluka; Sigma-Aldrich). Im-
munohistochemical controls included omission of the primary antibody
(n  2) and preincubation of the anti-MT2 antibody with a 100-fold
excess of its blocking peptide (n 2), which both completely prevented
any immunostaining (data not shown).
In four other rats, sections across the thalamus, collected at 50 m
intervals, were similarly processed for MT2 immunohistochemistry and
counterstained with cresyl violet, and the Rt nucleus carefully examined
by light microscopy at relatively high magnification (40 objective).
Extracellular recording of reticular thalamic neurons. Each adult male
Sprague Dawley rat, anesthetized with urethane (1 g/kg, i.p.), was placed
in a stereotaxic frame (David Kopf Instruments) and a catheter was in-
serted into a tail vein for systemic drug administration. Single-barreled
glass micropipettes (R&D Scientific Glass; tip diameter, 2–3 m) filled
with 2%pontamine sky blue dye in sodiumacetate (2M, pH7.5; electrode
impedance, 5–10M) were used for extracellular recording. A burr hole
was drilled and the micropipette lowered into the Rt at the following
stereotaxic coordinates: 2.56 mm AP, 3.5 mm L, and 5.0–6.5 mm
ventral relative to bregma (Paxinos and Watson, 2006).
Filtered (AC, 0.2–2 kHz) electrode signal was amplified (Bak Electron-
icsModel RP-I) and fed to an oscilloscope (BK Precision; 20MHz, 1522)
and an audio monitor. Spike shapes were digitalized by a CED 1401
interface system, processed on-line, and analyzed off-line by Spike 2
software, in parallel with analog-to-digital samplings of amplified (Grass,
P55) polygraphic signals (EEG; sampling rate, 100 or 200 Hz). Single-
unit activity was isolated with an amplitude spike discriminator. Rt
neurons were recognized by their long burst (50 ms) and accelerando-
decelerando bursting firing pattern (Fuentealba et al., 2004), followed by
tonic tail (Domich et al., 1986). Firing and burst neuronal activity was
analyzed with Spike 2 software for 3 min periods for each treatment:
basal, vehicle [propylene glycol (PG), saline 50%, 0.1 ml], and UCM765
(20 mg/kg). The burst of Rt cells consisted of a discharge of at least four
spikes (Contreras et al., 1993), with an onset defined by a maximum
interspike interval 20 ms and a preburst and postburst interval 100
ms (Domich et al., 1986). The longest interval allowed within a burst was
70 ms to include the tonic tail, which is merely the end of a spike barrage
(Domich et al., 1986).
Combined extracellular recording and intrathalamic microinfusion. In
six rats anesthetized with urethane (1 g/kg, i.p.), a Hamilton syringe (24
gauge) was lowered at an angle of 29o from the vertical axis into the Rt,
and 5.5 mm ventral from the brain surface. Vehicle (PG–saline 50%; 10
l) was slowly infused, and immediately after, an electrode was posi-
tioned into the Rt for in vivo electrophysiological recording of Rt neu-
rons. Once a stable firing Rt neuron was found, baseline activity was
recorded for 1–5 min, and then vehicle (0.1 ml, i.v.) was injected and the
neuronal activity recorded for an additional 3–5 min. Afterward,
UCM765 (20mg/kg, i.v) was injected, and the firing activity recorded for
3–5 min. The entire procedure did not last longer than 30 min.
In six other rats, 4P-PDOT (10 g in 10 l) was directly injected into
Rt with the Hamilton syringe, and the baseline activity of a single Rt
neuron as well as its activity after vehicle and UCM765 injection were
recorded as above.
Bilateral intrathalamic microinfusion and EEG/EMG recording in freely
moving rats. Rats were deeply anesthetized with equithesin (1 ml per
300 g, i.p.) and placed in a stereotaxic frame. Two stainless-steel guide
cannulas (23 gauge, 12 mm) were implanted bilaterally into the Rt at
stereotaxic coordinates 2.56 mm AP, 3.5/3.5 mm L, and 5 mm
ventral relative to bregma (Paxinos andWatson, 2006). Then, EEG/EMG
electrodes were positioned as above for themonitoring of the sleep–wake
cycle. EEG electrodes and cannulas were secured with dental acrylic.
Animals were habituated for 5 d as described above.
EEG and EMG were then recorded from 6:00 to 7:00 P.M., immedi-
ately after microinfusion of 2.5 l of vehicle (PG–saline 50%; n 5) or
UCM765 (10 g in 2.5 l; n 5) in each cannula.
Bilateral substantia nigra microinfusion and EEG/EMG recording in
freely moving rats. A similar experimental protocol was also used in eight
rats to test for eventual effects of UCM765 on sleep, if microinfused in
another brain region also displaying MT2 immunoreactive neurons, i.e.,
the substantia nigra, pars reticulata. Vehicle or UCM765 was infused at
the following stereotaxic coordinates:5.4mmAP,2.75/2.75mmL,
and 7.2 mm ventral relative to bregma (Paxinos and Watson, 2006).
Histological verification. At the end of extracellular recording and/or
microinfusion experiments, the brain was fixed by immersion in a 20%
formaldehyde solution and embedded in paraffin, and 10-m-thick sec-
tions collected at 50mintervals across thewhole thalamus or substantia
nigra were stainedwith cresyl violet and examined by lightmicroscopy to
identify the site of recording or microinfusion.
Statistical analyses. SigmaStat (version 3.5) and SPSS software (version
13) were used to analyze data. Results are expressed as the mean SEM.
Since assumptions of normality and variance homogeneity were satisfied
from all data, one-way, one-way repeated-measures, or two-way mixed-
design ANOVA (with factors as indicated in Results), followed by the
Student–Newman–Keuls (SNK) or Fisher test for post hoc comparison,
was used to determine differences. Student’s t test was used to compare
the effect of UCM765 with DZ in MT2 KO mice, and with vehicle in the
bilateral microinfusion experiments. Calculation of ED50 values was per-
formed using Microcal Software Origin (version 7). Relative changes in
the power of frequency bands (delta, theta, beta) as a percentage of con-
trol (vehicle or WT mice, respectively) were analyzed by one-way
ANOVA followed byBonferroni’s test for post hoc comparison. Statistical
values reaching p 0.05 were considered significant.
Results
Pharmacological properties of UCM765
UCM765 is a novel partial agonist exhibiting greater affinity for
MT2 (pKi 10.18) than forMT1 receptors (pKi 8.38), and even
greater MT2 affinity than MLT itself (pKi  9.62) (Rivara et al.,
2007). UCM765 does not display significant affinity for other
receptors, ion channels, and transporters, including those known
for their involvement in sleep–wake regulation, such as GABAA,
5-HT2A, and histamine receptors (data are from Cerep, Celle
L’Evescault, France; data not shown).
Based on the stimulation of basal [35S]GTPS binding, the
relative intrinsic activity values ofUCM765 towardMT1 andMT2
receptors have been estimated at 0.8 and 0.6, respectively (Rivara
et al., 2007). Since physiological concentrations of MLT induce a
desensitization and internalization of MT2 receptors (Gerdin et
al., 2003), we hypothesized that such a partial agonism might
represent a therapeutic advantage for obtaining submaximal re-
ceptor activationwithout desensitization.Moreover, UCM765 (5
mg/kg, i.v.) has acceptable pharmacokinetic properties (area un-
der the curve  68,954 min * ng/ml; Cmax  2562 ng/ml) and
half-life (T1/2 44 min) for hypnotic drug development, as well
as optimal hydrophilic–lipophilic balance (LogP of 2.64). This
unique pharmacological profile prompted us to examine its ef-
fects in vivo.
Pharmacological modulation of the sleep–wake cycle
With EEG/EMG measurements in freely moving rats, we first
queried whether a selective MT2 ligand might promote sleep.
Since MLT and its receptors have shown circadian variations
across the 24 h light/dark cycle, we recorded EEG/EMG activity
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during 24 h in four groups of rats, one
injected with vehicle (n 5) and the oth-
ers with 20 mg/kg (n 6), 40 mg/kg (n
5) or 60mg/kg (n 6) UCM765 every 4 h
(first injection at 6:00 P.M. for all groups).
This protocol was chosen on the basis of
the pharmacokinetic properties of
UCM765. As shown in Figure 1A–D, the
latency of the first long (2 min) episode
of NREMS was significantly affected by
the dose of UCM765 (F(3,18)  4.2; p 
0.01): 40 and 60 mg/kg respectively de-
creased latency by 59% and 49% (p 	
0.05).
Two-way ANOVA on total time in
NREMS indicated a significant main ef-
fect of doses (F(3,18)  4.80; p  0.013)
and phase of day (F(1,18)  89.27; p 	
0.001), with no interaction. In particular,
UCM765 prolonged the total amount of
NREMSduring the inactive/light phase by
48% (p 	 0.01) and 33% (p 	 0.05) at
doses of 40 and 60mg/kg, respectively. No
differences were observed between 40 and
60 mg/kg, suggesting that a plateau was
reached at these doses. The ED50 was 30.3
mg/kg for the NREMS total time in the
inactive phase. No significant effects of
UCM765 were reported on the total time
of REMS (Fig. 1C).
UCM765 decreased the time of wake-
fulness in the inactive/light phase (effect
of doses, F(3,18) 6.24, p 0.004; phase of
day, F(1,18)  75.11, p 	 0.001, with no
interaction). In particular, 40 and 60
mg/kg UCM765 decreased the total time
of wakefulness during the inactive/light
phase by 37% (p	 0.001) and 26% (p	
0.005), respectively (Fig. 1D). When the
effect of UCM765 (40 mg/kg) on NREMS
total time was compared to vehicle by 1 h
intervals over 24 h, a main effect of treat-
ment and time was observed (effect of
treatment, F(1,8) 8.32, p 0.02; effect of
time, F(23,184)  6.35, p 	 0.001, with no
interaction). The effect of UCM765 be-
came statistically significant mostly at the
end of the day (4:00–7:00 P.M.) (Fig. 1E),
when the expression of MT2 receptors is
maximal (Witt-Enderby et al., 2003).
These results indicated that UCM765 activated MT2 receptors
mostly during the inactive/light phase, without altering the 24 h
sleep–wake cycle. No significant modifications of REMS were
detected (Fig. 1E). The cumulative sleep effect was significant
only in the inactive light phase (Fig. 1F).
The effects of UCM765 on sleep were also compared to those
of the clinically used hypnotic benzodiazepine (DZ; Valium). As
shown in Figure 2, the group of rats treated with UCM765 (40
mg/kg every 4 h; n 5) and the group treated with DZ (2 mg/kg
every 12 h; n  6) both exhibited shorter onset latencies of the
first NREMS episode compared to the group of rats (n  5)
receiving vehicle every 4 h (Fig. 2A, left) (F(2,8)  9.0, p 	 0.01;
vehicle vs UCM765 orDZ, p	 0.01). UCM765 andDZ increased
total time of NREMS during the inactive/light phase only (Fig.
2A) (effect of treatment, F(2,13) 8.54, p 0.004; effect of phase
of day, F(1,13) 102.24, p	 0.001; with an interaction, F(2,13)
4.17, p  0.04). DZ, but not UCM765, markedly reduced the
number of NREMS episodes (Fig. 2A, center) (effect of treat-
ment, F(2,13) 7.04, p0.008, phase of day, F(1,13) 46.61, p	
0.001; with an interaction, F(2,13) 9.73, p 0.003; DZ vs vehicle
or UCM765, p 	 0.001). Only during the light phase did both
UCM765 andDZ increasemeanNREMS episode length (Fig. 2A,
right) (effect of treatment, F(2,13) 11.14, p0.002; phase of day,
F(1,13) 14.08, p0.002; with an interaction, F(2,13) 7.52, p
0.007). Both UCM765 and DZ increased REMS latency (F(2,8)
14.1, p 	 0.001), without apparent effects on REMS total time.
Figure 1. Promoting effect of UCM765 on sleep parameters (24 h recordings; light on at 7:30 A.M. and light off at 7:30
P.M.). Four different groups of rats were used: vehicle (n 5) and UCM765 at doses of 20 mg/kg (n 6), 40 mg/kg (n
5), and 60 mg/kg (n 6), injected subcutaneously every 4 h (first injection at 6:00 P.M.). The means SEM are shown. A,
UCM765 (40 and 60 mg/kg) decreased the latency of the first NREMS episode. B, UCM765 increased NREMS total time. C,
UCM765 had no effect on total time in REMS. D, UCM765 decreased wakefulness total time. ###p	 0.001, light versus dark
phase, by SNK post hoc test. E, Effects of UCM765 on NREMS and REMS total time: 1 h interval analysis during 24 h in 5 rats.
Top, UCM765 (40 mg/kg) increased the amount of NREMS during the inactive/light phase (white background), but not
during the active/dark phase (gray background), with a concomitant reduction in wakefulness total time. Bottom, REMS
was not modified by UCM765 (40 mg/kg). ###p 	 0.001, vehicle versus UCM765 treatment, by SNK post hoc test. F,
Cumulative differences between UCM765 and vehicle over 24 h EEG/EMG recording. Top, NREMS. Bottom, REMS. *p	 0.05,
**p	 0.01, ***p	 0.001 versus vehicle by SNK post hoc test.
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The number of REMS episodes appeared to be affected by phase
of day (Fig. 2B) (F(1,13) 5.57, p 0.03), but not by treatment.
Total time of wakefulness was significantly reduced after
treatment with either UCM765 or DZ during the inactive/light
phase only (Fig. 2C, left; effect of treatment, F(2,13)  9.28,
p0.003; phase of day, F(1,13) 75.15, p	 0.001, without inter-
action). DZ, but not UCM765, considerably decreased the num-
ber of episodes of wakefulness during the light phase (effect of
treatment, F(2,13)  7.95, p  0.006; phase of day, F(1,13) 
41.97, p 	 0.001; with an interaction, F(2,13)  9.17, p 
0.003). DZ, but not UCM765, significantly increased the mean
wakefulness episode length (Fig. 2C) (effect of treatment,
Figure 2. UCM765 (UCM) promotes NREMS like DZ [24 h recordings; light on at 7:30 AM, light off at 7:30 P.M.; UCM, 40mg/kg, s.c., every 4 h (n 5); DZ, 2 mg/kg, s.c., every 12 h (n 6); first
injection at 6:00 P.M.]. Themeans SEM are shown.A, Like DZ, UCM765 decreased the latency for NREMS. UCM765 and DZ increased NREMS during the inactive/light phase only (left). DZ, but not
UCM765, markedly reduced the number of NREMS episodes (center). UCM765 and DZ increased mean NREMS episode length during the light phase only (right). B, Both UCM765 and DZ increased
REMS latency,without apparent effect on REMS total time. The number of REMSepisodes appeared to be affected by phase of day, but not treatment. ThemeanREMepisode lengthwas not affected
by the treatment and phase of day. C, Both UCM765 and DZ decreased the total time of wakefulness during the inactive/light phase (left). DZ, but not UCM765, considerably decreased the number
of episodes of wakefulness during the light phase (center). DZ, but not UCM765, significantly increased the mean wakefulness episode length (right). D, Number of spindles. UCM765 and DZ
increased the number of spindles perminute during the light phase. *p	 0.05, **p	 0.01, ***p	 0.001 versus vehicle; #p	 0.05, ##p	 0.01, ###p	 0.001, DZ versus UCM765 or light versus
dark phase, by SNK post hoc test.
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F(2,13)  5.92, p  0.015; phase of day, F(1,13)  52.46, p 	
0.001, without interaction). Moreover, similarly to DZ,
UCM765 increased the number of spindles/min during the
inactive/light phase only (Fig. 2D) (effect of treatment, F(2,13) 
24.51, p 	 0.001; phase of the day, F(1,13)  110.20, p 	 0.001;
with an interaction, F(2,13) 13.33, p	 0.001).
The quality of sleep afterUCM765 andDZwas thus compared
using power spectra analysis during both light and dark phases
(Fig. 3). Upon calculation of the relative EEG power (vehicle set
at 100%) (Fig. 3, insets), a significant effect of treatment was
observed on the delta bands ofNREMS (F(2,15) 9.60, p 0.002)
and REMS (F(2,15)  209.43, p 	 0.001) and on beta bands of
NREMS (F(2,9) 13.71, p 0.002) andREMS (F(2,9) 16.08, p	
0.001), but not on theta. In particular, DZ produced a significant
decrease in the power of the delta band in both NREM and REM
sleep, and an increase of the peak of beta (10–12 Hz) (Fig. 3,
insets), as reported previously (Kopp et al., 2004; van Lier et al.,
2004). On the contrary, UCM765 produced a slight increase by
12% in delta of NREMS during the light phase. Similar findings
were also observed during the dark phase (Fig. 3, insets, bottom).
Sleep inMT2 andMT1 knock-out mice
To further characterize the role of MT2 and MT1 receptors in
sleep, the sleep parameters were also measured over the 24 h
light/dark cycle in mice lacking MT2 receptors (MT2 KO, n 5)
to compare themwith wild-typemice (WT, n 5) andwithmice
lacking MT1 receptors (MT1 KO, n 5).
Compared toWT andMT1 KOmice, MT2 KOmice showed a
decrease in NREMS (16%; p 0.017) during the inactive/light
phase only (Fig. 4A). On the contrary, MT1 KO mice showed an
increase in NREMS (40%; p  0.001) during the active/dark
phase (Fig. 4A) (effect of strain, F(2,12) 10.82, p 0.002; phase
of day, F(1,12)  79.40, p 	 0.001; with an interaction, F(2,12) 
6.14, p 0.015). MT2 KOmice displayed an increase of wakeful-
ness (19%; p  0.017) compared to WT and MT1 KO mice
during the light/inactive phase only, whereas MT1 KO mice
showed a decrease in wakefulness (24%; p 0.001) during the
dark/active phase (Fig. 4C) (effect of strain, F(2,12)  7.93, p 
0.006; phase of day, F(1,12)  94.40, p 	 0.001; with an interac-
tion, F(2,12) 7.47, p 0.008).
InWT andMT2 KOmice, REMS lasted longer in the inactive/
light phase (46%; p  0.005 and 50%; p 	 0.001, respec-
tively) than in the active/dark phase; in contrast, MT1 KO mice
spent equal time in REMS during both the light and dark phases
(p 0.69), indicating a disruption of the light/dark REMS cycle
(Fig. 4B) (effect of phase of day, F(1,12)  16.84, p  0.001; no
strain effect and interaction).
Altogether, these results suggested that MT2 receptors are
mostly involved in the maintenance of NREMS during the inac-
tive phase and not at all in REMS. Interestingly, the power spectra
analyses (Fig. 4D,E) during the light and the dark phases also
indicated a modified spectral power mostly in MT1 KO mice.
Upon calculating the relative EEG power (WT set at 100%) dur-
ing the light phase (Fig. 4D, insets), a significant effect of strain
Figure3. Power spectra ofNREMS (left traces) andREMS (right traces) after treatmentwith vehicle (bold lines), UCM765 (dotted lines), andDZ (thin lines) during the light (top) anddark (bottom)
phases. Insets, EEG power spectra after UCM765 (UCM) and DZ treatments relative to those of vehicle (100%, horizontal line) expressed as the mean percentage change (SEM). The mean
percentage power density was calculated as the mean power (in square microvolts) in each 0.5 Hz frequency bin divided by the total power (0–25 Hz) in the same epoch. *p	 0.05; **p	 0.01;
***p	 0.001, by Bonferroni’s post hoc test versus control (vehicle).
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Figure4. Twenty-fourhoursleeprecordingsinWT(n5),MT2KO(n5)andMT1KO(n5)mice(lightonat7:30AMandoffat7:30P.M.).Therecordingsstartedat6:00P.M.ThemeansSEMareshown.A,NREMS
duringthelightanddarkphases.ComparedtoWTandMT1KOmice,MT2KOmiceshowedadecreaseinNREMSduringtheinactive/lightphaseonly.MT1KOmiceshowedanincreaseinNREMSduringtheactive/darkphase.
B,REMSduringthelightanddarkphases.BothWTandMT2KOmicedisplayedlongerREMSduringthelight/inactivephasecomparedtotheactive/darkphase.ThisdifferencewasbluntedinMT1KOmice.C,Wakefulnessduring
thelightanddarkphases.MT2KOmiceshowedanincreaseofwakefulnesscomparedtoWTandMT1KOmice,duringthelight/inactivephaseonly.MT1KOmiceshowedadecreasedinwakefulnessduringthedark/activephase.
NotethatwakefulnessinthedarkphasedifferedbetweenMT1KOandMT2KOmice(p	0.001;datanotshown).*p	0.05,***p	0.001versusvehicle;
##p	0.01, ###p	0.001lightversusdarkphasebySNKposthoc
test.D,E,PowerspectraofNREMS(lefttraces)andREMS(righttraces) inWT(boldlines),MT2KO(dottedlines)andMT1KO(thinlines)miceduringthelight(D)anddark(E)phases. Insets,EEGpowerspectrainMT1andMT2
KOmice,expressedasameanpercentage(SEM)changerelativetothoseofcontrol(WT;100%;horizontalline).Themeanpercentagepowerdensitywascalculatedasthemeanpower(insquaremicrovolts)ineach0.5Hz
frequencybindividedbythetotalpower(0–25Hz) inthesameepoch.*p	0.05;**p	0.01;***p	0.001,byBonferroni’sposthoctestversuscontrol(WTmice).
Ochoa-Sanchez et al. • The MT2 Ligand UCM765 Promotes Sleep J. Neurosci., December 14, 2011 • 31(50):18439–18452 • 18445
was observed on the delta band of NREMS (F(2,15)  8.85, p 
0.003), on the theta bands of NREMS (F(2,27) 4.60, p 0.019)
and REMS (F(2,27) 5.98, p0.007), on sigma band of NREMS
(F(2,21) 131.22, p	 0.001), and onbeta bands ofNREMS (F(2,9)
828.75, p 	 0.001) and REMS (F(2,9)  4.98, p  0.035). For all
the bands, there were significant differencesmainly betweenMT1
KOandWTmice (p	 0.05). Similar findingswere obtained after
the analysis of NREMS and REMS power spectra during the dark
phase (Fig. 4E).
Selectivity of UCM765 for MT2 receptors
We then questioned whether the effects of UCM765 were linked
to its class properties [N-(substituted-anilinoethyl)amides], or to
its selective partial agonistic activity toward MT2 receptors. For
this purpose, we compared the effects of UCM765 to those of its
class congener UCM793 (Rivara et al., 2007), which exhibits a
nonselective MT1/MT2 profile of agonistic activity (MT1, pKi
9.09; MT2, pKi  9.19). In these experiments, sleep parameters
were measured between 6:00 and 9:00 P.M., a period during
which several NREMS and REMS episodes occur (Ruigt et al.,
1989).
As shown in Table 1 for TreatmentGroupA,UCM793 did not
modify the total time in NREMS and REMS. In much the same
way that the MT1/MT2 agonist ramelteon acts in rats (Fisher et
al., 2008) and humans (Erman et al., 2006), UCM793 at the dose
of 40 mg/kg (n  7) slightly reduced (15%) the latency of the
first long episode (2 min) of NREMS (vehicle, 26.4 2.8 min;
UCM793, 22.5  3.7 min). Thus, the effect of UCM765 on
NREMS appeared to be imputable to its selectivity toward MT2
receptors.
The MT2 antagonist 4P-PDOT is a reference compound ex-
hibiting good binding affinity for the cloned human MT2 recep-
tor (pKi 8.8) and a selectivity of at least 100-fold for MT2 over
the MT1 subtype (Boutin et al., 2005). To verify that the promo-
tion of NREMS by UCM765 is MT2 mediated, UCM765 (40 mg/
kg) was administered 10 min after the pretreatment with vehicle
or 4P-PDOT (10mg/kg, n 7). As shown in Table 1B, 4P-PDOT
blocked the effects of UCM765 onNREMS and wakefulness total
time, strongly suggesting that the maintenance of NREMS was
mediated by MT2 receptors. Indeed, two-way ANOVA showed a
significant interaction between treatment and pretreatment on
NREMS total time (F(1,20)  4.6, p  0.04) and total time of
wakefulness (F(1,20) 4.4, p 0.04). SNK post hoc test indicated
a significance (p	 0.05) of comparing 4P-PDOT plus UCM765
and vehicle plus UCM765.
Even though UCM765 is selective for MT2 receptors, it does
display a low affinity for MT1 receptors. To further confirm the
involvement of MT2 and determine which of the receptor sub-
types is involved in the NREMS promoting effect, we tested
UCM765 in MT2 KO (n 6), MT1 KO (n 6), andWT (n 8)
mice (Table 1, Group C). UCM765 decreased the latency to sleep
inWT (53%; p	 0.001) andMT1 KO (53%; p	 0.001), but
not in MT2 KO mice (effect of treatment, F(1,34)  27.8, p 	
0.001; strain, F(2,34) 3.9; p	 0.02, with no interaction). How-
ever, MT1 KO mice showed a long latency to the first onset of
sleep compared to WT (46%; p 	 0.01) after the injection of
vehicle. UCM765 increased NREMS total time in MT1 KO
(32%; p	 0.05), but not in MT2 KOmice (effect of treatment,
F(1,34) 12.0, p	 0.001; strain, F(2,34) 19.2, p	 0.001; with a
significant interaction, F(2,34) 4.5, p	 0.01), indicating that the
presence of MT2, but not of MT1, receptors is essential and nec-
essary for the restoration of NREMS (Table 1, Group C). REMS
latency was not modified in MT1 KO and MT2 KO mice, and
UCM765 had no effect on latency and total time in REMS.
UCM765 decreased the total time of wakefulness in WT (23%;
p	 0.001) and MT1 KOs (12%; p	 0.05), but not in MT2 KO
mice (Table 1, Group C) (effect of treatment, F(1,34) 10.4, p
0.003; strain, F(2,34) 13.9, p	 0.001; with a significant interac-
tion, F(2,34) 3.6, p 0.03).
Overall, the lack of effect inMT2 KOmice concurred with the
prior evidence that theNREMSpromoting effect ofUCM765was
selectivelymediated byMT2 receptors. To determinewhether the
Table 1. Selective effects of MT2 agonist UCM765 on standard sleep parameters
Treatment group NREM sleep latency (min) NREM sleep total time (min) REM sleep latency (min) REM sleep total time (min) Wakefulness total time (min)
A (rat)
Vehicle (n 7) 24.9 2.8 60.9 3.2 44.4 3.0 11.2 2.0 107.9 4.7
UCM793 40 mg (n 7) 22.5 3.6 55.3 5.6 61.6 15.0 10.9 2.2 113.2 6.4
UCM793 60 mg (n 6) 27.6 3.7 58.8 5.7 57.5 10.2 9.3 1.1 111.9 5.7
UCM793 80 mg (n 6) 22.8 30.9 48.3 5.2 56.4 9.2 8.3 0.4 123.4 5.9
B (rat)
Vehicle vehicle (n 6) 31.3 4.2 53.7 4.1 51.8 6.0 7.3 0.5 119.0 4.6
Vehicle UCM765 40 mg (n 6) 19.5 2.7* 72.6 5.0*,# 75.3 11.2 7.8 1.2 99.6 5.8*,#
4P-PDOT 10 mg vehicle (n 6) 25.8 3.4 60.5 5.2 75.6 9.0 8.2 1.5 111.3 6.3
4P-PDOT 10 mg UCM765 40 mg (n 6) 20.7 3.2 57.4 5.7 65.8 11.4 6.9 0.8 115.7 6.2
C (mouse)
WT vehicle (n 8) 26.3 1.9 64.4 4.4 52.5 6.2 6.4 1.3 109.2 5.7
WT UCM765 40 mg (n 8) 12.4 1.6** 89.3 5.6*** 71.6 10.0 6.1 1.0 84.6 5.7***
MT1 KO vehicle (n 6) 38.5 4.5 50.5 3.9 63.3 5.0 4.0 0.5 125.6 4.0
MT1 KO UCM765 40 mg (n 6) 18.0 2.6*** 66.8 3.8* 69.1 11.7 3.5 0.5 109.7 3.0*
MT2 KO vehicle (n 6) 27.9 2.6 51.0 4.0 63.8 9.5 6.3 0.8 122.7 4.2
MT2 KO UCM765 40 mg (n 6) 20.0 1.4 48.8 4.1 65.5 11.1 5.8 1.4 125.4 5.8
D (mouse)
MT2 KO vehicle (n 6) 27.9 2.6 51.0 4.0 63.8 9.5 6.3 0.8 122.7 4.2
MT2 KO DZ 2 mg (n 4) 10.1 0.7* 76.0 2.8** 62.1 12.3 5.1 1.0 98.9 2.3**
EEG/EMG recordings are from 6:00 to 9:00 P.M. (lights off at 7:30 P.M.). Data are expressed asmean SEM; the number of animals per group is indicated in brackets. Group A, Lack of effect of increasing doses of the nonselectiveMT1 /MT2
agonist class congener UCM793 (40, 60, and 80 mg/kg, s.c.) in rats. Group B, Blockade of UCM765 effects by the MT2 antagonist 4P-PDOT in rats. Treatment with vehicle or UCM765 (40 mg/kg, s.c.) was administered 10 min after the
pretreatmentwith vehicle or 4P-PDOT (10mg/kg, s.c.). *p	 0.05, vehicleUCM765 versus vehicle vehicle; #p	 0.05, 4P-PDOTUCM765 versus vehicleUCM765, by SNK post hoc test. No differenceswere observed in latency and
total time in REMS. Group C, Effects of UCM765 (40 mg/kg, s.c.) on sleep parameters in MT2 and MT1 receptor KO andWTmice. UCM765 decreased the latency to sleep inWT andMT1 KO, but not in MT2 KOmice. UCM765 increased NREMS
total time in MT1 KO, but not in MT2 KOmice. REMS latency was not modified in MT1 KO andMT2 KOmice, and UCM765 had no effect on latency and total time in REMS. UCM765 decreased the total time of wakefulness in WT andMT1 KO,
but not inMT2 KOmice. *p	 0.05; **p	 0.01; ***p	 0.001 by Fisher’s PLSD test comparing vehicle versus UCM765 treatment. GroupD, Diazepam (2mg/kg, s.c.) was still active inMT2 KOmice. *p	 0.05; **p	 0.01 by Student’s t test.
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reduction in NREMS observed in MT2 KO mice was due to the
lack of MT2 receptors rather than to impairment in other sleep-
related neurotransmission systems, MT2 KO mice were treated
with the GABAA agonist DZ (Table 1, GroupD). As in rats, DZ in
MT2 KOmice (n 4) decreased the latency of the first episode of
sleep (64%; p	 0.05, Student’s t test), enhanced NREMS total
time (49%; p	 0.002), and tended to decrease REMS total time
(21%) and time inwakefulness (20%; p	 0.003), thus suggest-
ing that the GABAergic regulation of sleep was intact in these mice.
Immunohistochemical localization of MT2 receptors
MT2 receptor immunoreactivity was detected in numerous ana-
tomical regions across rat brain (Fig. 5). Strong labeling of neu-
ronal cell bodies and proximal dendrites was consistently
observed in Rt (Fig. 5A–E), septum, CA3 of dorsal hippocampus
(Fig. 5F), substantia nigra reticulata and red nucleus (Fig. 5G),
supraoptic nucleus (Fig. 5H), oculomotor nuclei, and ventral
tegmental nucleus. In high-resolution micrographs obtained af-
ter counterstaining with cresyl violet (Fig. 5E), it was apparent
that all neurons in Rt were immunoreactive (arrows). Neuronal
labeling was moderate in the ventral pallidum, globus pallidus,
other sectors of hippocampus (e.g., the dentate gyrus), paraven-
tricular nucleus of the hypothalamus, and inferior colliculus. In
hippocampus, the sparse distribution of labeled neuronswas sug-
gestive of interneurons. Therewas no somatodendritic labeling in
suprachiasmatic nucleus (Fig. 5I), but this nucleus appeared
slightly darker than surrounding areas, perhaps due to punctate
(axon terminal) labeling. No MT2 labeling was observed in the
whitematter and numerous other graymatter structures, notably
in cerebral cortex, striatum, lateral hypothalamic area, habenular
nuclei, substantia nigra pars compacta, periaqueductal gray, and
raphe nuclei.
UCM765 activates neurons of the reticular thalamic nucleus
Given the presence of MT2 receptors in the Rt nucleus (Fig.
5A–D) and the importance of this nucleus in the induction of
NREMS (Steriade, 1999), we first examined the effects of system-
ically administeredUCM765 (20mg/kg, i.v.) on the firing activity
of these neurons. As reported in Table 2, UCM765 (n  8), but
not vehicle (n 8), elicited an increase in firing activity (91%,
p 	 0.001), percentage of spikes in burst (134%; p  0.002),
andmean spike per burst (50%; p 0.02) in all neurons tested.
Figure 6A illustrates an integrate histogram of a single-unit re-
cording displaying the classical pattern of a typical Rt neuron
before and after the UCM765 intravenous injection. A sustained
increase in firing (second trace) and burst (third trace) activities
was observed immediately after the injection ofUCM765.On top
of Figure 6 (insets), the typical accelerando-decelerando pattern of
Rt neurons is shown at highermagnification. Figure 6B is the plot
of mean interspike intervals against the number of spikes per
burst in the basal condition and after vehicle and UCM765 injec-
tions for all Rt neurons tested (n  8). UCM765 increases the
number of spikes within bursts, but does not change the pattern
of interspike interval distribution.
To confirm that the firing andburst activation of Rt neuronswas
due to a direct activation of MT2 receptors localized within the nu-
Figure 5. Lightmicroscopic visualization ofMT2 receptor immunoreactivity. Top left, Alignment between human and ratMT2 protein sequences, andWestern blots performed on homogenates
from hippocampus (Hi), Harderian gland (HG; negative control), septum (S), and hypothalamus (Hy). Polyclonal anti-MT2 receptor antibodies decorate a doublet of40 kDa corresponding to the
MT2 receptor. A–I, Particular aspects of the anatomical distribution of the MT2 receptor immunoreactivity in adult rat brain. A–E, Low- (A) and higher-magnification pictures (B–E) of the
somatodendritic MT2 receptor labeling in Rt. A corresponds to the middle rostrocaudal level across the nucleus (outlined) at which electrophysiological recordings andmicroinjections were made.
Note the lack of immunoreactivity in adjacent thalamic nuclei, and notably in the ventral posterolateral thalamic nucleus (VPL).B, C, The neuronal MT2 labeling in the rostral (B) and the caudal (C)
thirds of Rt (outlined).D iswithin themiddle third of Rt and illustrates the somatodendritic nature ofMT2 immunoreactivity.E is froma similar area asD in a section counterstainedwith cresyl violet.
As exemplified at arrows, all Rt neurons areMT2 immunoreactive.F–I, Other brain regions displayingMT2 immunoreactivity: dorsal hippocampus (F ), red nucleus (R) and substantia nigra reticulata
(SNR) (G), supraoptic nucleus (H ), and suprachiasmatic nucleus (I ). Scale bars: A, C, F–I, 250m; D, E, 50m. 3V, Third ventricle; AVVL, anteroventral, ventrolateral thalamic nucleus; CA1, CA2,
CA3, Ammon’s horn sectors; DG, dentate gyrus; ic, internal capsule; ox, optic chiasma.
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Table 2. Firing and burst activity parameters of reticular thalamic neurons recorded in vivo in the basal condition and after administration of vehicle and UCM765
(10mg/kg, i.v.)
Spontaneous firing rate activity Spontaneous burst activity
Firing rate
(Hz)
Interspike interval
(s)
Coefficient of
variation (%)
Number of bursts
(3 min)
Spikes in
bursts (%)
Spikes per
burst
Burst interspike
interval (ms)
Burst length
(ms)
Intraburst firing
rate (Hz)
Treatment groups
Basal (n 8) 2.3 0.7 1.2 0.4 72.0 21.0 23.4 8.0 16.2 3.1 6.6 1.2 13.0 2.2 99.0 31.8 118.5 36.5
Vehicle (n 8) 2.2 0.8 1.2 0.3 72.8 15.0 19.1 6.3 21.8 7.2 6.5 1.2 11.1 1.7 74.5 17.1 121.8 31.0
UCM765 (20 mg; n 8) 4.4 0.9*** 0.3 0.1* 68.6 13.4 55.0 8.0*** 37.9 8.0** 9.9 1.5* 16.9 2.8 164.6 32.1 67.4 7.4
Statistics F(2,14)12.8 F(2,14)4.0 F(2,14)0.04 F(2,14)14.3 F(2,14)9.9 F(2,14)4.7 F(2,14)1.2 F(2,14)2.3 F(2,14)1.7
p	 0.001 p 0.04 p 0.9 p	 0.001 p 0.002 p 0.02 p 0.3 p 0.1 p 0.2
Data are expressed as mean SEM from eight neurons (1 neuron per rat). *p	 0.05; **p	 0.01; ***p	 0.001, by SNK post hoc test.
Figure 6. UCM765 in vivo enhanced the firing rate and rhythmic burst activity of Rt neurons.A, Single-neuron activity recording (first trace), with integrated histogramof spontaneous firing rate
(second trace), burst event (third trace), and burst instantaneous frequency (fourth trace) after injection of vehicle or UCM765 (20mg/kg, i.v.). Arrows indicate the start of injection. The time scale
(20 s) applies to all four traces. B, Plot of mean interspike intervals (in milliseconds) against the number of spikes per burst, for 3 min in the basal condition and immediately after the intravenous
injection of vehicle or UCM765. The mean from eight neurons (1 neuron per rat) is shown. C, Typical waveform of Rt neurons. Top insets, Amplification of recordings after vehicle and UCM765
injections, visualizing the typical accelerando-decelerando pattern of Rt neurons characterized by an initial partwith frequency acceleration (200–250Hz) and deceleration, followed by long-lasting
tonic barrage of spikes of100 Hz (tail). Note that after UCM765 injection, the number of spikes per burst increases. Time scale, 50 ms.
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cleus, theMT2 antagonist 4P-PDOT(10g/10l;n7)was locally
infused in the Rt before the intravenous injection of UCM765. The
increase of firing and burst activation of Rt neurons after UCM765
injectionwas prevented by the local infusion of 4P-PDOT, confirm-
ing that this effectwasmediatedbyMT2 receptorspresentwithin the
nucleus [two-way ANOVA analysis for factors infusion (vehicle or
4P-PDOT) and treatment (basal, vehicle or UCM765), F(2,10) 
10.23, p 0.004] (Fig. 7A–D).
In all brains in which the recording sites could be localized
histologically, the electrode tract ended in the dorsal Rt, either in
its anterior or in its middle third, rostro-
caudally (Fig. 7B). In a single case inwhich
the Rt was missed, the electrode tract was
found immediately adjacent, but lateral,
to the internal capsule.
Microinfusion of UCM765 in Rt but not
in substantia nigra induces NREMS
To further confirm that UCM765 pro-
moted NREMS by acting on Rt neurons,
the compoundwas bilaterally infused into
the Rt nuclei in nonanesthetized freely
moving rats (n 5), in which EEG/EMG
activity was simultaneously recorded for
1 h (6:00–7:00 P.M.). UCM765 (10g bi-
laterally) significantly decreased NREMS
latency compared to vehicle (49%,
9.2 2.4 min vs 18.2 3.0; t 2.31; 8 df;
p 0.04). Moreover, UCM765 increased
NREMS total time (93%; t  2.81; 8
df; p  0.02) and decreased wakefulness
(31%; t 2.49; 8 df; p 0.03) without
affecting REMS (Fig. 8A–C). In three
brains examined histologically after bilat-
eral microinfusion, the lesions produced
by the cannulas and deposits of pon-
tamine sky blue encroached on the dorsal
Rt, again in its rostral ormiddle third, ros-
trocaudally (Fig. 8B).
WhenUCM765was bilaterallymicroin-
fused into the substantia nigra pars reticu-
lata (n  8), another area rich in MT2
receptor (Fig. 5G), no changes in the sleep–
wake parameters were displayed (Fig.
8D–F) compared to vehicle, indicating that
activation of MT2 receptors located into Rt
are necessary for UCM765 to promote
sleep.
Discussion
This is the first demonstration that acti-
vation of MT2 receptors by the novel se-
lective partial agonist UCM765 induces
and promotes NREMS. This effect of
UCM765 is dependent on MT2 receptors,
since it was nullified by the pharmacolog-
ical blockade or genetic deletion of these
receptors.
The promotion of NREMS is likely the
result of the burst activation of Rt neu-
rons. Indeed, the increase of Rt neural ac-
tivity induced by systemic administration
of UCM765 paralleled the NREMS en-
hancement, and its local microinfusion
into Rt was sufficient to produce this effect. When UCM765 was
microinfused into the substantia nigra, another area rich in MT2
receptor, but with less impact on sleep, there were no apparent
changes in sleep–wake parameters.
MT2 receptors have not been implicated previously in the
regulation of sleep, except in a recent study suggesting that the
MT2 agonist IIK7 may transiently perturb the sleep–wake cycle
(Fisher and Sugden, 2009). Thus far, MT2 receptors had been
mostly implicated in the regulation of circadian rhythm, even
Figure 7. The effects of UCM765 on reticular thalamic neurons are mediated by MT2 receptors. Microinfusion of the MT2
antagonist 4P-PDOT into rat Rt prevents the firing rate and burst neuronal activation induced by UCM765 (20 mg/kg, i.v.; n 7)
A, Spontaneous firing rate (in hertz) of Rt neurons after either microinfusion of vehicle (Veh) into Rt followed by intravenous
injection of vehicle orUCM765 (UCM), ormicroinfusion of 4P-PDOT (10g) followedby intravenous injection of vehicle orUCM765
(20 mg/kg). *p	 0.05, Veh inf. plus UCM765 versus Veh inf. plus Veh and versus Veh inf. plus basal; #p	 0.05, Veh.inf. plus
UCM765 versus 4P-PDOT inf. plus UCM765, by SNK post hoc test. The means SEM from seven neurons (1 neuron per rat) are
shown. B, Histological control of a recording site in Rt. The electrode track may be traced into the inner aspect of the dorsal Rt, at
amiddle rostrocaudal level across thenucleus. VPL,Ventral posterolateral thalamicnucleus; ic, internal capsule. Scalebar, 250m.
C, Plot ofmean interspike intervals (ms) against the number of spikes per burst for 3min. Themean from seven neurons (1 neuron
per rat) is shown. D, Single-neuron activity recording example (first trace), with integrated histogram of spontaneous firing rate
(second trace), burst event (third trace), andburst instantaneous frequency (fourth trace); 4P-PDOT (10g)wasmicroinfused into
Rtprior the intravenous injectionsof vehicle andUCM765 (20mg/kg). The time scale (20 s) applies to all four traces. Arrows indicate
the start of intravenous injection.
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though controversial results had been ob-
tained by in vitro and in vivo techniques.
For example, in brain slices fromWT and
MT2 KO mice, but not MT1 KO mice,
MLT was found to inhibit neuronal firing
in the suprachiasmatic nucleus, whereas
the phase shift of neuronal firing rhythms
induced by the MT1/MT2 agonist 2-iodo-
MLT was of smaller magnitude in supra-
chiasmatic nucleus (SCN) brain slices
from MT1 KO mice than WTs (Liu et al.,
1997). Moreover, in vivo studies have
demonstrated that MLT induces phase
shifts in WT and MT2 KO mice (Hudson
et al., 2005), but not in MT1 KO mice
(Dubocovich et al., 2005), whereas circa-
dian rhythms appear to be unaltered in
MT2 KOmice (Jin et al., 2003). These ob-
servations altogether suggest thatMT1 but
notMT2 receptors are directly involved in
circadian regulation. Indeed, prior studies
having hypothesized a role forMT2 recep-
tors in phase shift presented several pit-
falls; the experiments in vivo had been
performed with relatively low doses of
melatonin receptor ligands (Dubocovich
et al., 1998), and those using SCN slices
had inevitably eliminated the whole brain
circuitry (Hunt et al., 2001). Nevertheless,
although sleep and circadian rhythms are
coupled, they are presumably generated
by different neuronal mechanisms, in
keeping with the notion that the time
course of their ontogenic development is
not consistently comparable (Mirmiran et
al., 2003).
The bulk of our results suggest that
MT2 receptors play a specific role in
NREMS regulation during the inactive/
light phase, whereas MT1 receptors are
likely involved in the 24 h sleep–wake cy-
cle, sleep regulation in the active phase,
and overall spectral activity. Indeed, MT1
KO mice exhibited increased NREMS as-
sociated with a modified 24 h sleep–wake
cycle. Conversely, the presence ofMT1 re-
ceptors in MT2 KO mice left the 24 h
sleep–wake cycle intact with a decrease in
NREMS total time. In keeping with this
view, two functions associated with
NREMS (Marshall and Born, 2007), long-
term potentiation in the hippocampus
and memory consolidation (Larson et al.,
2006), have been shown to be impaired in
MT2 KO mice.
Our polysomnographic recordings
suggest that the effects of UCM765 on
sleep are different from those of nonselec-
tive, MT1/MT2, class congeners. In par-
ticular, the congener UCM793 slightly decreased sleep onset,
butwithout effect onNREMSmaintenance, similar to ramelteon,
suggesting that the affinity of these compounds for both MLT
receptors accounts for their effect on sleep onset, whereas selec-
tivity toward MT2 receptors results in a more incisive effect on
sleep onset as well as NREMS maintenance. As two receptors for
the same neurotransmitter may have divergent functions, selec-
tivity for a single receptor can provide a therapeutic advantage.
Figure 8. Local microinfusion of UCM765 into reticular thalamus promotes NREMS, whereas microinfusion into substan-
tia nigra pars reticulata (SNR) does not affect sleep–wake parameters in freely moving non-anesthetized rats. A–C, Effects
of bilateral microinfusion of UCM765 (10g) into the Rt and concomitant EEG/EMG recordings from 6:00 to 7:00 P.M. The
means  SEM from five rats are shown. A, UCM765 decreased the latency of the first episode of sleep. *p 	 0.05. B,
Histological control of bilateral microinfusion sites. On both sides, the lesion and deposit of pontamine sky blue is located
in the middle third of the dorsal Rt. Abbreviations are as in Figure 7B. C, UCM765 increased the total time of NREMS and
reduced wakefulness. *p	 0.05, t test. D–F, Effects of bilateral microinfusion of UCM765 (10g) into SNR and concom-
itant EEG/EMG recordings from 6:00 to 7:00 P.M. Themeans SEM from eight rats are shown.D, Latency of the first NREMS
episode. E, Histological control of microinfusion site: the pontamine sky blue deposit is locatedwithin the SNR. F, Total time
of NREMS, REMS, and wakefulness. Scale bars: 250m.
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For example, in hippocampal slices, MT1 andMT2 receptor acti-
vation appears to differentiallymodulate GABAA receptor func-
tion, suggesting that MLT, through activation of different
receptor subtypes, may exert opposite effects in the same brain
area (Wan et al., 1999). Similarly, MT1 and MT2 receptors have
also been shown to act in an opposite manner on the vascular
system, producing vasoconstriction and vasodilatation, respec-
tively (Doolen et al., 1998). Our data also suggest differential
functions in sleep; indeed NREMS is decreased in MT2 KO mice
during the inactive/light phase and increased in MT1 KO mice
during the active/dark phase.
As visualized by light microscopic immunohistochemistry,
many regions of rat brain, more or less tightly implicated in dif-
ferent aspects of sleep, contain neurons bearing MT2 receptors.
The focus of the present study was on Rt, because in rodents, Rt
neurons are known to be all GABAergic and to provide inhibitory
inputs to thalamic relay cells (Jones, 2007). Rt is of great impor-
tance for sleep regulation (Steriade, 1999), innervating thalamo-
cortical relay neurons with a feedback inhibition that influences
thalamocortical rhythm generation (Deleuze and Huguenard,
2006). During episodes of NREMS, Rt neurons discharge in a
slow, rhythmic burst-firing mode that is transmitted to thalamic
relay nuclei and modulated by corticothalamic inputs, resulting
in awidespread synchronization across neuronal assemblies (Ste-
riade et al., 1991) and a modification of consciousness (Tononi
and Massimini, 2008).
Another remarkable finding of the present study was the in-
duction by UCM765 of the burst activity of Rt neurons. This
activity pattern was MT2-mediated since it was abolished by the
intrathalamic microinfusion of a selective MT2 receptor antago-
nist. Since this burst activity promotes NREMS, MT2 receptors
may thus be viewed as a key component in sleep regulation. The
presence of MT2 receptors on Rt GABA neurons reinforces the
evidence for an allosteric interaction between MT2 and GABAA
receptors (Wan et al., 1999). The hypnotic effects of MLT are
indeed blocked by BZ-GABAA antagonists in experimental ani-
mals (Wang et al., 2003a). However, the fact that MT2 ligands
have a distinct profile fromBZ, and that BZ are still active inMT2
KOs, suggest thatMT2 ligandsmightmodulate GABAergic activ-
ity in a differential manner compared to BZ/GABAA receptors,
using, for example, a different intracellular pathway.
The signaling cascade through which UCM765 exerts its hyp-
notic effects remains to be elucidated, as well as the subregions of
Rt involved in the promotion of NREMS mediated by MT2 re-
ceptors. Moreover, the potential effects of UCM765 in other
brain structures known to be implicated in sleep, such as the
basal forebrain (which has projections to Rt), the ventrolateral
preoptic nucleus, and the suprachiasmatic nucleus, await
some clarification. Nevertheless, the selective promotion of
NREMS through the activation of Rt neurons designates MT2
receptors as a promising novel target for the treatment of
insomnia and sleep disorders.
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